CG Oncology (CG Oncology) Insider Ownership : 0.98 % (As of Jun. 07, 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CG Oncology's insider ownership is 0.98%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CG Oncology's Institutional Ownership is 17.15%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CG Oncology's Float Percentage Of Total Shares Outstanding is 99.02%.

CG Oncology Insider Ownership Historical Data

The historical data trend for CG Oncology's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Insider Ownership Chart

CG Oncology Historical Data

The historical data trend for CG Oncology can be seen below:

	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Insider Ownership	1.03	0.98	0.98	0.98	0.98

CG Oncology Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024